Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.

vobramitamab duocarmazine (MGC018) - MacroGenics

A-1331852 - AbbVie

http://www.ncbi.nlm.nih.gov/pubmed/40964329

Colm Morrissey; Galina Semenova; Ilsa Coleman; John K Lee; Michael C Haffner; Peter S Nelson; Roman Gulati; Ruth Dumpit; Sander Frank; Wanting Han

Sep 18, 2025